Exelixis, Inc. (NASDAQ:EXEL) Director Alan M. Garber sold 11,250 shares of the business’s stock in a transaction on Tuesday, January 8th. The shares were sold at an average price of $23.00, for a total transaction of $258,750.00. Following the transaction, the director now owns 72,579 shares in the company, valued at approximately $1,669,317. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Exelixis stock opened at $23.76 on Friday. The company has a current ratio of 8.66, a quick ratio of 8.54 and a debt-to-equity ratio of 0.01. Exelixis, Inc. has a 52 week low of $13.42 and a 52 week high of $31.79. The stock has a market cap of $7.08 billion, a P/E ratio of 46.59, a P/E/G ratio of 1.46 and a beta of 2.09.
Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Thursday, November 1st. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.22. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. The firm had revenue of $225.40 million for the quarter, compared to analyst estimates of $174.14 million. During the same period in the previous year, the company posted $0.26 earnings per share. The business’s revenue was up 47.8% on a year-over-year basis. Research analysts anticipate that Exelixis, Inc. will post 1.3 earnings per share for the current fiscal year.
Several analysts have recently issued reports on the stock. Oppenheimer set a $40.00 target price on shares of Exelixis and gave the stock a “buy” rating in a research note on Thursday, November 1st. Goldman Sachs Group began coverage on shares of Exelixis in a research report on Monday, September 17th. They set a “neutral” rating and a $22.00 price target on the stock. BidaskClub upgraded shares of Exelixis from a “sell” rating to a “hold” rating in a report on Saturday, December 1st. ValuEngine upgraded shares of Exelixis from a “strong sell” rating to a “sell” rating in a report on Saturday, December 1st. Finally, Guggenheim initiated coverage on Exelixis in a research report on Monday, September 17th. They set a “buy” rating for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $28.38.
ILLEGAL ACTIVITY NOTICE: “Exelixis, Inc. (EXEL) Director Sells $258,750.00 in Stock” was published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/01/12/exelixis-inc-exel-director-sells-258750-00-in-stock.html.
Exelixis Company Profile
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
See Also: What is a stock split?
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.